Month: February 2013

Home » Archives for February 2013

VIDEO: Dr. Laurence Klotz, “Navigating treatment options for localized prostate cancer”

  January 2013 Scotiabank Awateness Night Dr.Laurence Klotz, MD, FRCSC Professor, Department of Surgery, University of Toronto Chief, Division of Urology, Sunnybrook Health Sciences Centre Chair, Canadian Uro-Oncology Group and NCIC GU Site Group Editor in Chief (founding), Canadian Journal of Urology Chair, Global GU Oncology Group For localized prostate cancer, the choice of treatment is becoming less straightforward as preferences shift to less aggressive, less intrusive, and increasingly sophisticated approaches. This presentation provides guidance and insight…with focus on active surveillance, focal therapy, MRI imaging, and recent developments in surgery. CLICK ON THE ARROW TO START THE VIDEO  “Navigating treatment …

VIDEO: Dr. Laurence Klotz, “Navigating treatment options for localized prostate cancer” Read More »

Tea May Lower Prostate Cancer Risk

New findings add to mounting evidence suggesting that tea consumption may lower the risk of developing prostate cancer. The findings are based on a population-based case-control study conducted in King County, Washington. The study, by Milan S. Geybels, MSc, of the Department of Epidemiology, Maastricht University, Maastricht, The Netherlands, and colleagues examined associations between PCa risk and tea and coffee consumption. The tea-related analysis focused on 863 PCa cases and 863 controls; the coffee-related analysis included 894 cases and 860 controls. Read the article.

New prostate cancer test could change treatment.

Schulich School of Medicine & Dentistry professor Hon Leong has developed a new blood test which could detect the potential for prostate cancer earlier. Thousands of men face a prostate biopsy following higher-than-normal results from their annual prostate-specific antigen (PSA) test, the traditional screening for prostate cancer. But recent studies have shown three in four of these biopsies were unnecessary, leading to 165,000 unnecessary procedures and 6,930 related hospitalizations each year. Read more at: http://medicalxpress.com/news/2013-02-prostate-cancer-treatment.html#jCp

Recent Developments in Treatments for Metastatic Castration-resistant Prostate Cancer—A Mechanistic Perspective

Abstract Over the past decade, the treatment landscape in metastatic castration-resistant prostate cancer (CRPC) has markedly changed, with the introduction of three new chemotherapeutic agents. The mechanism of CRPC is not fully understood, but it may result from multiple pathways, including a loss or androgen receptor (AR) specificity and increased downstream signalling activity that provide multiple targets for therapeutic agents. For some years, docetaxel was the mainstay of treatment in CRPC, but recently, cabazitaxel (a microtubule inhibitor), sipuleucel-T (a cancer vaccine), and abiraterone acetate (a CYP17 inhibitor) were approved for CRPC treatment. In Phase III clinical trials, these agents have …

Recent Developments in Treatments for Metastatic Castration-resistant Prostate Cancer—A Mechanistic Perspective Read More »

Scroll to Top